Human induced pluripotent stem cell (hiPSC) derived models are heavily explored as alternatives for animal models used in preclinical discovery and safety assessment. Here, Jean-Pierre Valentin from UCB
Biopharma will provide a retrospective review on three compounds which showed preclinical and clinical cardiac liabilities. To understand to what extend hiPSC-derived cardiomyocytes could have predicted their side effects, the three compounds
were tested using Ncardia’s human iPSC-derived cardiomyocytes in combination with ACEA’s xCELLigence Cardio ECR system. The hiPSC-derived models demonstrated value in refining the integrated cardiac safety assessment.
Using real-time kinetic analysis, this physiologically-relevant human cardiac model allows for the detection of both acute as well as chronic drug-induced toxicities. In the last few years, this predictive validity of hiPSC-derived cardimyocytes
has also been substantiated by various case studies and publications. As a result, pharma are slowly integrating these assays into their early safety assessment to detect potential safety hazards and improve compound selection prior to entering
the costly and time-consuming animal studies.
- Uses of iPSC-derived cell types in cardiac screening/safety applications
- Humanizing drug discovery/development, "mimic the clinic"
- 'Real-world' examples / case studies
Jean-Pierre Valentin, PhD, HDR, ERT, FSBiol, FRCPath, DSP
Senior Director, Head of Investigative Toxicology
UCB Biopharma SPRL
Jean-Pierre holds a Ph.D. in Physiology & Pharmacology 1990, from the University of Montpellier, France. Following a post-doc at UCSF, Jean-Pierre joined the Pierre Fabre Research Centre (1992-98) where he contributed to the discovery and
progression into development of 3 candidate drugs. He joined AstraZeneca to build from inception, develop and lead the Department of Safety Pharmacology where he contributed to the safety evaluation of ~200 candidate drugs across a wide range
of therapy areas, leading to the development and successful registration of several marketed products. In February 2014, he joined UCB-Biopharma as Senior Director Head of Investigative Toxicology, based in Belgium. He is a member of several
scientific societies; Past President of the Safety Pharmacology Society; co-chair of the HESI subcommittee on QT/Arrhythmia, and the ABPI-NC3Rs-Animal Model Framework. He is involved in training and education programs and is author/co-author
of several patents and >180 peer review publications and book chapters.
Xiaoyu Zhang, PhD
Senior Scientist, R&D/Applications
ACEA Biosciences Inc
Xiaoyu Zhang received her Ph.D. in Cell Molecular and Development Biology from the University of California, Riverside, conducted postdoctoral training and research at Burnham Insatute for Medical Research. Dr. Zhang joined ACEA Biosciences in
2011. She has been leading the FDA CiPA studies, cardiac safety screening program and RTCA Cardio/CardioECR applicaaons development.
Greg Luerman, PhD
Technical Director (North America)
Dr. Greg Luerman is Technical Director at Ncardia. Following his graduate studies at the University of Louisville School of Medicine, Dr. Luerman earned a Michael J Fox Foundation postdoctoral fellowship within the Pfizer Neuroscience Research
Unit where he lead bioassay development on a Parkinson’s disease therapeutic team. He moved on to establish a preclinical cardiac safety/tox and drug discovery assays at ChanTest (now Charles River). Now at Ncardia, Dr. Luerman oversees
North American scientific operations.